BIOLOGICAL ASPECTS OF NEW MOLECULAR THERAPIES FOR NEUROPATHOLOGIES.

Introduction: Addressing the formidable therapeutic hurdles posed by Alzheimer's disease (AD), our study delves into the central role of amyloid β 1-42 (Aβ1-42) protein aggregation in its onset. Aim: Our investigation aims to assess the therapeutic potential of the isoindolinone derivative 3-(3-oxoisoindolin-1-yl)pentane-2,4-dione (ISOAC1) against the Aβ1-42-induced toxicity. Material and methods: Employing a combination of thioflavin T fluorescence assay and biological and cellular approaches, alongside other experimental methods, we explored ISOAC1's ability to mitigate Aβ1-42 aggregation and toxicity. Results and conclusions: Our study unveils ISOAC1's capacity to disrupt Aβ1-42 aggregation and impede its transition towards β-sheet structures. Furthermore, our findings shed light on ISOAC1's binding mechanisms with Aβ1-42, indicating its promise as a therapeutic agent. ISOAC1 emerges as a compelling neuroprotective compound, offering novel avenues for AD treatment. [ABSTRACT FROM AUTHOR]